Blood Protein Disorders

11 clinical trials · Condition

Record	Firm	Date
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (NCT05298683)	Hellenic Society of Hematology	2022-05-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (NCT05280275)	Hellenic Society of Hematology	2022-04-13
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (NCT05147493)	Hellenic Society of Hematology	2022-04-01
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084)	Celularity Incorporated	2020-05-12
Bedside Assessment of Coagulation in Post-partum Hemorrhage by Thromboelastography (TEG ®6S) (NCT03592303)	Assistance Publique - Hôpitaux de Paris	2018-08-01
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma (NCT02155634)	Celgene	2014-07-01
Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients (NCT00751322)	Mayo Clinic	2008-08-01

Every clearance here is in the API, with alerts when new ones post.